Pillar Biosciences and AstraZeneca today announced an expansion of their existing laboratory access program for NGS-based kitted liquid biopsy tumor profiling to include China.

Pillar Biosciences 和阿斯利康今天宣布，将其现有的基于 NGS 的液态活检肿瘤分析试剂盒的实验室访问计划扩展到包括中国。

This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local availability of plasma-based tumor profiling at leading clinical laboratories in China, the partnership seeks to accelerate diagnostic turnaround times and improve access to precision oncology solutions..

这项扩大合作旨在通过液体活检测试提供快速、经济高效且具有临床可操作性的基因组洞察。通过增加中国领先临床实验室中基于血浆的肿瘤分析的本地可用性，该合作伙伴关系力求加快诊断周转时间，并改善对精准肿瘤学解决方案的获取。

China faces one of the world's highest cancer burdens, accounting for approximately 24% of new global cancer cases and 30% of cancer-related deaths, according to the World Health Organization's GLOBOCAN 2022 report. Lung, colorectal, and liver cancers remain among the most prevalent, and access to early detection and molecular diagnostics continues to be a significant healthcare challenge.

根据世界卫生组织GLOBOCAN 2022报告，中国面临的癌症负担为全球最高之一，约占全球新发癌症病例的24%和癌症相关死亡的30%。肺癌、结直肠癌和肝癌仍然是最常见的癌症类型，而获得早期诊断和分子诊断仍然是一个重要的医疗挑战。

By expanding localized liquid biopsy testing, this collaboration supports China's ongoing initiatives to enhance early cancer detection, precision diagnostics, and equitable access to targeted therapies..

通过扩大局部液态活检测试，这项合作支持了中国为加强早期癌症检测、精准诊断和公平获取靶向治疗而持续进行的举措。

As part of the initiative, AstraZeneca, Pillar Biosciences, and Shanghai Zhengu Biological Technology Co., Ltd. (Zhengu) will collaborate to support assay validation in local hospital laboratories and facilitate the implementation of Pillar's liquid biopsy panels to enable localized tumor profiling..

作为该计划的一部分，阿斯利康、Pillar Biosciences 和上海真固生物科技有限公司（真固）将合作支持当地医院实验室的检测验证，并推动Pillar液体活检面板的实施，以实现本地化的肿瘤分析。

'Expanding access to decentralized, high-quality molecular testing is critical to improving outcomes for cancer patients,' said Dan Harma, Chief Commercial Officer, Pillar Biosciences. 'By enabling local laboratories to perform in-house next-generation sequencing, we can reduce turnaround times, lower costs, and ensure that oncologists have faster access to actionable insights that guide personalized treatment decisions.'.

“扩大获取分散式、高质量分子检测的渠道对于改善癌症患者的治疗效果至关重要，”Pillar Biosciences首席商务官丹·哈玛表示。“通过使本地实验室能够进行内部下一代测序，我们可以缩短周转时间、降低成本，并确保肿瘤医生更快获得指导个性化治疗决策的可行见解。”

About Pillar Biosciences

关于支柱生物科学

Pillar Biosciences is a leader in Decision Medicine™—leveraging highly accurate and sensitive next-generation sequencing (NGS) technologies to optimize precision therapy selection for cancer patients, from tumor profiling to treatment selection and recurrence monitoring. Powered by its proprietary SLIMamp® and PiVAT® technologies, Pillar's localized testing approach helps reduce diagnostic costs, improve turnaround times, and expand access to high-quality NGS testing globally..

Pillar Biosciences是决策医学™领域的领导者——利用高度准确和灵敏的下一代测序（NGS）技术，优化癌症患者从肿瘤分析到治疗选择及复发监测的精准治疗方案。凭借其专有的SLIMamp®和PiVAT®技术，Pillar的本地化检测方法有助于降低诊断成本、缩短周转时间，并在全球范围内扩大高质量NGS检测的可及性。

The company offers more than 20 NGS testing kits in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences is headquartered in Natick, Massachusetts.

该公司提供20多种NGS检测试剂盒，涵盖IVD或RUO格式，并有多款检测组合处于不同开发阶段。Pillar Biosciences总部位于马萨诸塞州的纳蒂克。

For more information, visit pillarbiosci.com and connect with us on LinkedIn.

欲了解更多信息，请访问 pillarbiosci.com 并在 LinkedIn 上与我们联系。

Source: prnewswire.com

来源：prnewswire.com